Crohn’s Candidates Capitalize On TNF Inhibitor Risks At DDW Meeting
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ocera Therapeutics is going against the tide of biologics for Crohn’s disease as its adsorptive carbon agent AST-120 enters Phase III in fistulizing Crohn’s disease.